Clonal heterogeneity of lymphoid malignancies correlates with poor prognosis

Cancer Science

Volumn 105, Issue 7, 2014, Pages 897-904

  Suguro, Miyuki ^a   Yoshida, Noriaki ^a   Umino, Akira ^a   Kato, Harumi ^a   Tagawa, Hiroyuki ^b   Nakagawa, Masao ^c   Fukuhara, Noriko ^d   Karnan, Sivasundaram ^e   Takeuchi, Ichiro ^f   Hocking, Toby D ^g   Arita, Kotaro ^a   Karube, Kennosuke ^a   Tsuzuki, Shinobu ^a   Nakamura, Shigeo ^h   Kinoshita, Tomohiro ^a   Seto, Masao ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

^g MCGILL UNIVERSITY   (Canada)

^h NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Array comparative genomic hybridization; Heterogeneity; Malignant lymphoma; Patient outcome assessment; Tumor cell population

Indexed keywords

ARTICLE; ATP1B2 GENE; BURKITT LYMPHOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CDKN2A GENE; CDKN2B GENE; CELL POPULATION; CHROMOSOME 17P; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME G BAND; CHROMOSOME GAIN; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; FOLLICULAR LYMPHOMA; GENE; GENETIC HETEROGENEITY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NUCLEOTIDE SEQUENCE; NUMERICAL CHROMOSOME ABERRATION; ONCOGENE MYC; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; SAT2 GENE; SHBG GENE; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ARRAY COMPARATIVE GENOMIC HYBRIDIZATION; HETEROGENEITY; MALIGNANT LYMPHOMA; PATIENT OUTCOME ASSESSMENT; TUMOR CELL POPULATION;

BURKITT LYMPHOMA; CHROMOSOMES, HUMAN, PAIR 8; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE DELETION; GENE DOSAGE; HUMANS; LYMPHOMA; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS;

EID: 84904251500     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12442     Document Type: Article

References (38)

1. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med 2013; 368: 842-51.
2. Yang T, Rycaj K, Liu Z et al. Cancer stem cells: constantly evolving and functionally heterogeneous therapeutic targets. Cancer Res 2014; doi: 10.1158/0008-5472.CAN-14-0266.
3. Landau DA, Carter SL, Stojanov P et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-26.
4. Campbell PJ, Yachida S, Mudie LJ et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-13.
5. Bochtler T, Stolzel F, Heilig CE et al. Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J Clin Oncol 2013; 31: 3898-905.
6. Villamor N, Lopez-Guillermo A, Lopez-Otin C et al. Next-generation sequencing in chronic lymphocytic leukemia. Semin Hematol 2013; 50: 286-95.
7. Brioli A, Melchor L, Cavo M et al. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol 2014; 165: 441-54.
8. Liu F, Yoshida N, Suguro M et al. Clonal heterogeneity of mantle cell lymphoma revealed by array comparative genomic hybridization. Eur J Haematol 2013; 90: 51-8.
9. Yoshida N, Umino A, Liu F et al. Identification of multiple subclones in peripheral T-cell lymphoma, not otherwise specified with genomic aberrations. Cancer Med 2012; 1: 289-94.
10. Seto M. XV. Malignant lymphoma as a consequence of clonal evolution. Hematol Oncol 2013; 31(Suppl 1): 84-8.
11. Umino A, Nakagawa M, Utsunomiya A et al. Clonal evolution of adult T-cell leukemia/lymphoma takes place in the lymph nodes. Blood 2011; 117: 5473-8.
12. Ciriello G, Miller ML, Aksoy BA et al. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013; 45: 1127-33.
13. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2008.
14. Fukuhara N, Nakamura T, Nakagawa M et al. Chromosomal imbalances are associated with outcome of Helicobacter pylori eradication in t(11;18)(q21;q21) negative gastric mucosa-associated lymphoid tissue lymphomas. Genes Chromosom Cancer 2007; 46: 784-90.
15. Nakagawa M, Nakagawa-Oshiro A, Karnan S et al. Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/lymphoma. Clin Cancer Res 2009; 15: 30-8.
16. Tagawa H, Karnan S, Suzuki R et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005; 24: 1348-58.
17. Tagawa H, Karube K, Guo Y et al. Trisomy 3 is a specific genomic aberration of t(14;18) negative follicular lymphoma. Leukemia 2007; 21: 2549-51.
18. Tagawa H, Suguro M, Tsuzuki S et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 2005; 106: 1770-7.
19. Hocking TD, Boeva V, Rigaill G et al. SegAnnDB: interactive web-based genomic segmentation. Bioinformatics 2014; 30: 1539-46.
20. Braggio E, Dogan A, Keats JJ et al. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Mod Pathol 2012; 25: 651-60.
21. Morin RD, Mendez-Lago M, Mungall AJ et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298-303.
22. Fabbri G, Rasi S, Rossi D et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208: 1389-401.
23. Pasqualucci L, Trifonov V, Fabbri G et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43: 830-7.
24. Lohr JG, Stojanov P, Lawrence MS et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012; 109: 3879-84.
25. Bea S, Colomo L, Lopez-Guillermo A et al. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol 2004; 22: 3498-506.
26. Bea S, Valdes-Mas R, Navarro A et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 2013; 110: 18250-5.
27. Puente XS, Pinyol M, Quesada V et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-5.
28. Villamor N, Conde L, Martinez-Trillos A et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2013; 27: 1100-6.
29. Li C, Kim SW, Rai D et al. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood 2009; 113: 6681-90.
30. Oscier D, Owen R, Johnson S. Splenic marginal zone lymphoma. Blood Rev 2005; 19: 39-51.
31. Young KH, Leroy K, Moller MB et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008; 112: 3088-98.
32. Green TM, Young KH, Visco C et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30: 3460-7.
33. Johnson NA, Slack GW, Savage KJ et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30: 3452-9.
34. Navarro A, Clot G, Royo C et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012; 72: 5307-16.
35. Miyazaki K, Yamaguchi M, Suzuki R et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 2011; 22: 1601-7.
36. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006; 6: 663-73.
37. Velimezi G, Liontos M, Vougas K et al. Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. Nat Cell Biol 2013; 15: 967-77.
38. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006; 127: 265-75.